- Home
- SOWG vs GOVX Comparison
SOWG vs GOVX Comparison
Compare SOWG & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- GOVX
- Stock Information
- Founded
- SOWG 2010
- GOVX 2001
- Country
- SOWG United States
- GOVX United States
- Employees
- SOWG N/A
- GOVX N/A
- Industry
- SOWG Packaged Foods
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- GOVX Health Care
- Exchange
- SOWG Nasdaq
- GOVX Nasdaq
- Market Cap
- SOWG 8.8M
- GOVX 7.6M
- IPO Year
- SOWG N/A
- GOVX N/A
- Fundamental
- Price
- SOWG $0.82
- GOVX $0.69
- Analyst Decision
- SOWG
- GOVX Strong Buy
- Analyst Count
- SOWG 0
- GOVX 3
- Target Price
- SOWG N/A
- GOVX $10.67
- AVG Volume (30 Days)
- SOWG 115.8K
- GOVX 668.1K
- Earning Date
- SOWG 11-12-2025
- GOVX 11-11-2025
- Dividend Yield
- SOWG N/A
- GOVX N/A
- EPS Growth
- SOWG N/A
- GOVX N/A
- EPS
- SOWG N/A
- GOVX N/A
- Revenue
- SOWG $9,271,376.00
- GOVX $6,143,044.00
- Revenue This Year
- SOWG $6.81
- GOVX N/A
- Revenue Next Year
- SOWG N/A
- GOVX N/A
- P/E Ratio
- SOWG N/A
- GOVX N/A
- Revenue Growth
- SOWG N/A
- GOVX 1943.07
- 52 Week Low
- SOWG $0.51
- GOVX $0.43
- 52 Week High
- SOWG $13.55
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- SOWG 54.79
- GOVX 41.54
- Support Level
- SOWG $0.70
- GOVX $0.65
- Resistance Level
- SOWG $0.88
- GOVX $0.73
- Average True Range (ATR)
- SOWG 0.07
- GOVX 0.04
- MACD
- SOWG 0.02
- GOVX -0.00
- Stochastic Oscillator
- SOWG 73.50
- GOVX 23.24
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.